PPT Slide

FDA Review of Primary Endpoint

Agreement that data supported the finding of a treatment effect, but FDA has questioned the

• Robustness of the finding

• Clinical meaningfulness of the treatment effect

Previous slide

Next slide

Back to first slide

View graphic version